Pregabalin Capsule
Product Images NDC 50228-652

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50228-652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-caps-100mg-500s-count (Pregabalin Caps 100mg 500s Count)

FDA Label Image

Pregabalin-caps-100mg-90s-count (Pregabalin Caps 100mg 90s Count)

FDA Label Image

Pregabalin-caps-150mg-500s-count (Pregabalin Caps 150mg 500s Count)

This text describes a medication containing 150 mg of pregabalin in each capsule. It provides instructions for dosage and usage, storage conditions, and dispensing information. The medication guide can be printed from the website mentioned. It is manufactured by ScieGen Pharmaceuticals, Inc. and dispensed in child-resistant containers. The text also includes the NDC number and quantity information for dispensing.*

FDA Label Image

Pregabalin-caps-150mg-90s-count (Pregabalin Caps 150mg 90s Count)

This is a description of a medication capsule containing 150 mg of pregabalin. The dosage and usage instructions are mentioned, along with storage conditions. It also refers to a medication guide that should be dispensed to each patient. The capsule is presented in child-resistant containers. The manufacturer is identified as JscieGen Pharmaceuticals.*

FDA Label Image

Pregabalin-caps-200mg-500s-count (Pregabalin Caps 200mg 500s Count)

This text provides information about a medication containing 200 mg of pregabalin per capsule. The dosage and use details are not available in this excerpt but can be found in the accompanying prescribing information. Dispensing should be done in tight, child-resistant containers. The manufacturer is ScieGen Pharmaceuticals, Inc., located in Hauppauge, NY. The medication guide can be accessed at the provided website.*

FDA Label Image

Pregabalin-caps-200mg-90s-count (Pregabalin Caps 200mg 90s Count)

Each capsule contains 200 mg pregabalin. The medication is stored at 25°C and should be dispensed in tight, child-resistant containers. For detailed information on dosage and use, refer to the accompanying prescription information. This prescription is for 90 capsules and is intended for Rx use only. Manufactured by ScieGen Pharmaceuticals, Inc. located in Hauppauge, NY.*

FDA Label Image

Pregabalin-caps-225mg-500s-count (Pregabalin Caps 225mg 500s Count)

This text provides information about pregabalin capsules, with each capsule containing 225 mg of pregabalin. The dosage and usage instructions should be followed by referring to the prescribing information accompanying the product. It is advised to store the capsules at 25°C with excursions permitted between 15°C to 30°C. The medication should be dispensed in tight, child-resistant containers. The Medication Guide can be printed from the provided website. The capsules are manufactured by ScieGen Pharmaceuticals, Inc. with the NDC 50228-651-05. It is specified to dispense the Medication Guide to each patient and that the product includes 500 capsules for prescription use only.*

FDA Label Image

Pregabalin-caps-225mg-90s-count (Pregabalin Caps 225mg 90s Count)

This information pertains to Pregabalin capsules containing 225 mg of the active ingredient. It includes details such as the NDC number, storage instructions, and manufacturer information. The medication guide can be printed from the provided website for each patient.*

FDA Label Image

Pregabalin-caps-25mg-500s-count (Pregabalin Caps 25mg 500s Count)

This text provides information about a medication in capsule form containing 25 mg of pregabalin. It includes guidelines for dosage and storage, prescribing information, and a link to the Medication Guide. The medication is manufactured by ScieGen Pharmaceuticals, Inc. located in Hauppauge, NY. The NDC number for the product is 50228-645-05. It is recommended to dispense the Medication Guide to each patient along with the capsules.*

FDA Label Image

Pregabalin-caps-25mg-90ct (Pregabalin Caps 25mg 90ct)

This text provides information about capsules containing 25 mg pregabalin, with prescribing and dispensing details, including dosage and storage instructions. It also mentions the need to dispense the Medication Guide along with the capsules to each patient. The capsules are manufactured by ScleGen Pharmaceuticals, Inc. in Hauppauge, NY.*

FDA Label Image

Pregabalin-caps-300mg-500s-count (Pregabalin Caps 300mg 500s Count)

Each capsule contains 300 mg pregabalin. The medication should be stored at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It is recommended to dispense in tight, child-resistant containers. The Medication Guide can be printed from the provided website. Manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY with the NDC number 50228-652-05. This is a prescription-only medication consisting of 500 capsules.*

FDA Label Image

Pregabalin-caps-300mg-90s-count (Pregabalin Caps 300mg 90s Count)

This description provides information about a medication containing 300 mg of pregabalin per capsule, with instructions to store at 25°C and dispense with the accompanying Medication Guide to each patient. The manufacturer is ScleGen Pharmaceuticals, Inc. located in Hauppauge, NY.*

FDA Label Image

Pregabalin-caps-50mg-500s-count (Pregabalin Caps 50mg 500s Count)

This is a medication description for Pregabalin capsules containing 50 mg per capsule. It includes instructions on dosage and storage, as well as a link to the Medication Guide. The capsules are dispensed in child-resistant containers and the Medication Guide should be given to each patient. Manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY. The NDC number for the capsules is 50228-646-05.*

FDA Label Image

Pregabalin-caps-50mg-90s-count (Pregabalin Caps 50mg 90s Count)

Each capsule contains 50 mg of pregabalin. It is important to store the medication at controlled room temperature and dispense it in child-resistant containers. The Medication Guide should be provided to each patient. This drug is manufactured by ScleGen Pharmaceuticals, Inc. located in Hauppauge, NY.*

FDA Label Image

Pregabalin-caps-75mg-500s-count (Pregabalin Caps 75mg 500s Count)

Each capsule contains 75 mg of progabain. The medication is available in child-resistant containers and should be stored at controlled room temperature between 20-25°C (68-77°F). The Medication Guide can be printed from the website provided by the manufacturer, ScieGen Pharmaceuticals, Inc. This prescription medicine is dispensed with 500 capsules.*

FDA Label Image

Pregabalin-caps-75mg-90s-count (Pregabalin Caps 75mg 90s Count)

Each capsule contains 75 mg pregabalin. The medication guide should be dispensed with each patient. The capsules should be stored at controlled room temperature. The manufacturer is SciGen Pharmaceuticals.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

This text includes information about the percent of patients improved after taking Pregabalin 160 mg for three days. It also shows a chart with the percentage improvement in pain from baseline.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

FDA Label Image

Figure 4 (Pregabalin Fig04)

This information provides data on the improvement in pain from baseline for parent of patients who were given pregabalin 200 mg three times a day or pregabalin 100 mg three times a day, as well as a placebo. The numbers indicate the level of pain improvement for each group.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

This is a summary of a clinical trial evaluating the efficacy of three different treatments: Fregabalin 100 mg three times a day, Pregataiin 80 mg three times a day, and Placebo. The data table includes the number of patients improved and percentage improvement in pain from the baseline for each treatment.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

This text appears to be a summary of different studies comparing the effects of varying doses of a medication versus a placebo. The text shows the dosages tested (150mg/day, 300mg/day, 600mg/day) and states that the results were statistically significant compared to the placebo group. The studies are labeled as E1, E3, and S5.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

This is a graph showing the percentage of patients who experienced improvement in pain levels when taking different doses of pregabalin daily compared to a placebo. The graph indicates that the group taking 450mg of pregabalin daily had the highest percentage of patients showing improvement, followed by the group taking 300mg of pregabalin daily. The group taking a placebo had the lowest percentage of patients showing improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This is a table showing the estimated percentage of subjects without LTR (Likely to Return) over a period of time in a study comparing Progabain versus Placebo. The percentages range from 0% to 100% at different time points displayed in the table. The X-axis shows the number of days, from 0 to 180, while the Y-axis presents the percentages.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

Percent of Subjects Improved 210 220 230 240 Percent Improved from Baseline to Week 12 BOCF Pregetalin 260 Placeso 100*

FDA Label Image

Figure 12 (Pregabalin Fig11)

This data table presents the percentage of subjects improved over the course of the study, specifically from baseline to week 16 using BOCF method. The table shows the values 100, 210, 220, 230, 240, 250, 260, 270, 280, and 200. The improvement percentages for the subjects receiving pregabalin and placebo are outlined, aiding in evaluating the effectiveness of the treatment.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

This information appears to be a table showing responder rates at different doses for a study. The responder rates are listed in percentages for different dose levels. The table also mentions a placebo group and the doses administered in mg/kg/day. The data suggests that the responder rates range from 22.6% to 40.6% for the different dose levels being evaluated.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

The text provides a formula for calculating CLCT (Creatinine Clearance) based on the age and weight of the patient, and the serum creatinine level. The formula is [140 - age (years)] x weight (kg) for all patients, and for female patients, this value should be multiplied by 0.85. In addition, the text mentions using 72 x serum creatinine (mg/dL) for calculating CLCT.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.